Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Meds A-Z

Trilostane

Detailed information about Trilostane

Official label facts Owner quick guide first Marketing clearly labeled
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Reviewed / Updated / Sources

Reviewed: Not available

Updated: February 12, 2026, 7:40 PM UTC

Sources:

Pet Owner Quick Guide

Start here first for the simple next-step summary.

Used for:

For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism in dogs.

What to watch for:

  • Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches
  • Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors
  • Hypoglycaemia (1 reports)
  • Hypernatremia (1 reports)
  • Hyperkalaemia (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

What to ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Safety & side effects

What to watch:

  • Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches
  • Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors
  • Hypoglycaemia
  • Hypernatremia
  • Hyperkalaemia

Most reported reactions:

  • Hypoglycaemia (1 reports)
  • Hypernatremia (1 reports)
  • Hyperkalaemia (1 reports)

When to call your vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Data freshness: source data appears current.

Latest refresh: Mar 21, 2026, 10:01 a.m.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 7:40 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 18, 2026, 10:03 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 17, 2026, 11:05 AM UTC
Image for Trilostane

Trilostane

Drug type: Generic ingredient • Branded profile • FDA branded products available

Species: Dog

Manufacturer: Not available (source)

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Dog
Manufacturer: Not available
Form: Capsule
Identifiers:
NADA: 141291 NDC Package: 17033-105-30 NDC Package: 17033-110-30 NDC Package: 17033-111-30 NDC Package: 17033-112-30 NDC Package: 17033-130-30 NDC Package: 17033-160-30 NDC Package: 58597-7038-6 NDC Package: 62157-361-01 NDC Package: 62157-401-01 NDC Package: 62157-556-01 NDC Package: 62157-557-01 NDC Package: 62157-560-01 NDC Package: 62157-596-01 NDC Package: 62157-927-01 NDC Package: 62991-2736-1 NDC Package: 62991-2736-2 NDC Package: 62991-2736-3 NDC Package: 62991-2736-4 NDC Package: 62991-2736-5
Source metadata:

Warnings / Contraindications

Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.

  • High: Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
21
Species represented
2
Grouped by Body System
Digestive (5) · Loss of appetite, Drooling, Diarrhea Skin & allergy (1) · Head twitching Behavior (1) · Behavioral disorder (unspecified) Other (25) · Injection site tenderness, Inappropriate urination, Hypoglycaemia
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Dog 1

Species coverage: Dog (16) Cat (16)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Digestive Dog Non-serious - 1
Other Dog Non-serious - 1
Other Cat Non-serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Skin & allergy Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Digestive Dog Non-serious - 1
Other Cat Serious - 1
Digestive Dog Serious - 1
Other Cat Serious - 1
Digestive Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Behavior Cat Non-serious - 1
Other Cat Serious - 1
Digestive Dog Serious - 1
Other Cat Serious - 1
Other Cat Non-serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Source metadata:

Storage & Handling

Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and handle with care.

Documents

Owner handouts and official technical documents are grouped for faster access.

Owner handouts (0)
  • No owner handouts linked yet.
Official label / PI (1)
  • VETORYL N141291C0048.pdf · Labeling
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadLabeling/914
SPL (1)
  • VETORYL® CAPSULES · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/2017/VETORYL%C2%AE%20CAPSULES
FOI (2)
  • UCM173123.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/856
  • UCM508381.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/855
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 7:40 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 18, 2026, 10:03 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 17, 2026, 11:05 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: VETORYL® CAPSULES
Case-reported brands (openFDA): MSK
Catalog species: Dog • FDA-labeled species: Dog
Rx/OTC: RX
Form/route: Capsule • Oral
Applications: NADA 141-291
Documents: 3 (FOI: 2) • SPL: 1 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 21 • Cat 8 • View
Case summaries: 12 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Usage_Inferred (0.78), Usage_Inferred (0.78)
Diagnosis Codes
ICD10_CM: E24.9
Cushing syndrome, unspecified

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors. (Contraindication, High)
Top reaction signals
Hypoglycaemia (1) Hypernatremia (1) Hyperkalaemia (1) Hyperglycaemia (1) Haematuria (1) Gastrointestinal irritation (1) Enlarged kidney (1) Elevated blood urea nitrogen (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 141291 NDC Package: 17033-105-30 NDC Package: 17033-110-30 NDC Package: 17033-111-30 NDC Package: 17033-112-30 NDC Package: 17033-130-30 NDC Package: 17033-160-30 NDC Package: 58597-7038-6 NDC Package: 62157-361-01 NDC Package: 62157-401-01 NDC Package: 62157-556-01 NDC Package: 62157-557-01 NDC Package: 62157-560-01 NDC Package: 62157-596-01 NDC Package: 62157-927-01 NDC Package: 62991-2736-1 NDC Package: 62991-2736-2 NDC Package: 62991-2736-3 NDC Package: 62991-2736-4 NDC Package: 62991-2736-5 NDC Package: 63732-2018-4 NDC Package: 63732-2018-5 NDC Package: 63732-2018-6 NDC Package: 63732-2018-7
Package NDC Product NDC Form / Route Status
17033-105-30 17033 -
17033-110-30 17033 -
17033-111-30 17033 -
17033-112-30 17033 -
17033-130-30 17033 -
17033-160-30 17033 -
58597-7038-6 58597 -
62157-361-01 62157 -
62157-401-01 62157 -
62157-556-01 62157 -
62157-557-01 62157 -
62157-560-01 62157 -
62157-596-01 62157 -
62157-927-01 62157 -
62991-2736-1 62991 -
62991-2736-2 62991 -
62991-2736-3 62991 -
62991-2736-4 62991 -
62991-2736-5 62991 -
63732-2018-4 63732 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • VETORYL N141291C0048.pdf • Official label • Official • May 20, 2024
    FDA official labeling for application 141291
  • UCM508381.pdf • FOI summary • Official • May 20, 2024
    FDA FOI summary for application 141291
  • UCM173123.pdf • FOI summary • Official • May 20, 2024
    FDA FOI summary for application 141291

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 6 Clinical 2 Manufacturer 0 Marketing 0
Current Field Facts
  • overdose_info: Overdose can cause acute adrenal insufficiency with signs of collapse, severe weakness, and gastrointestinal upset. Immediate emergency treatment with IV fluid… (Clinical, 2026-02-12)
  • storage_handling: Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and … (Clinical, 2026-02-12)
  • contraindications: Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE … (Official, 2026-02-12)
  • side_effects: Common side effects include decreased appetite, vomiting, diarrhea, and lethargy; may lead to an Addisonian crisis if cortisol is overly suppressed. (Official, 2026-02-12)
  • usage: Used to treat hyperadrenocorticism (Cushing’s disease) in dogs by inhibiting cortisol production. Requires regular monitoring via ACTH stimulation tests and el… (Official, 2026-02-12)
Recent Revisions
  • side_effects updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
VETORYL® CAPSULES
RX
Trilostane
Capsule • Oral
Label highlights
Official documents
Dechra, Ltd. NADA 141-291 Approved May 20, 2024

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Each capsule contains 5, 10, 20, 30, 60, or 120 mg trilostane.
Dogs
Indication

For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism in dogs.

Dosage
The starting dose for the treatment of hyperadrenocorticism in dogs is 1.0 to 3.0 mg/lb (2.2 to 6.7 mg/kg) once a day based on body weight and capsule size. Capsules should be administered with food.
Limitations

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents
  • Summary
    This supplement provides for the addition of a 10 mg capsule size.
  • Summary
    For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs.
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Usage

Used to treat hyperadrenocorticism (Cushing’s disease) in dogs by inhibiting cortisol production. Requires regular monitoring via ACTH stimulation tests and electrolyte checks.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.

Side Effects

Common side effects include decreased appetite, vomiting, diarrhea, and lethargy; may lead to an Addisonian crisis if cortisol is overly suppressed.

Source: FDA openFDA • Reference

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Loss of appetite (1) • Dog Drooling (1) • Dog Diarrhea (1) • Dog Decreased appetite (1) • Dog Appetite loss (1) • Dog

Showing top 5 for Digestive.

Skin & allergy
Head twitching (1) • Dog

Showing top 5 for Skin & allergy.

Behavior
Behavioral disorder (1) • Cat

Showing top 5 for Behavior.

Other
Injection site tenderness (1) • Dog Inappropriate urination (1) • Cat Hypoglycaemia (1) • Cat Hypocortisolaemia (1) • Dog Hypernatremia (1) • Cat
Show more (20)
Hyperkalaemia (1) • Cat Hyperglycaemia (1) • Cat Haematuria (1) • Cat General illness (1) • Dog Gastrointestinal irritation (1) • Dog Enlarged kidney (1) • Cat Elevated serum alkaline phosphatase (1) • Dog Elevated blood urea nitrogen (1) • Dog Elevated alanine aminotransferase (1) • Dog Drug prescribing error (1) • Cat Dilated renal pelvis (1) • Cat Diabetes mellitus (1) • Cat Death by euthanasia (1) • Cat Death (1) • Dog Collapse NOS (1) • Dog Azotaemia (1) • Cat Anisocoria (1) • Cat Accidental exposure (1) • Cat Abnormal ultrasound finding (1) • Cat Abnormal movement NOS (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, ['Terrier - Bull - American Pit', 'Dog (unknown)'], Female, 8 month, 32.205 kilogram • Drug: MSK, Unassigned, Oral, Dose: 60 Milligram per animal, Frequency: 1 per day • Reactions: Head twitching, Abnormal movement NOS, Injection site tenderness • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-055018
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 8.00 Month
  • Weight: 32.205 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Unassigned
  • Dose: 60 Milligram per animal
  • Frequency: 1 per day
Reactions Reported:
Head twitching Abnormal movement NOS Injection site tenderness
Outcomes: Ongoing

Dog, Dog (unknown), Female, 14 year, 17.3 kilogram • Drug: MSK, Capsule, Dose: 10 Milligram per animal, Frequency: 12 per hour • Reactions: Collapse NOS, Death • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-055856
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Female
  • Age: 14.00 Year
  • Weight: 17.300 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Form: Capsule
  • Dose: 10 Milligram per animal
  • Frequency: 12 per hour
Reactions Reported:
Collapse NOS Death
Outcomes: Died

Dog, Dachshund (unspecified), Male, 14 year, 9.25 kilogram • Drug: MSK, Unknown • Reactions: Unwell, Loss of appetite, Malaise, Whining, Drooling… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-055407
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 14.00 Year
  • Weight: 9.250 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Unwell Loss of appetite Malaise Whining Drooling Lack of efficacy - NOS
Outcomes: Outcome Unknown

Dog, ['Pug', 'Crossbred Canine/dog'], Female, 14 year, 10 kilogram • Drug: MSK, Capsule, Oral, Dose: 15 Milligram per animal, Frequency: 24 per hour • Reactions: Diarrhea, Vomiting, Elevated blood urea nitrogen, Appetite loss, Hyperkalaemia… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-055954
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 14.00 Year
  • Weight: 10.000 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Capsule
  • Dose: 15 Milligram per animal
  • Frequency: 24 per hour
Reactions Reported:
Diarrhea Vomiting Elevated blood urea nitrogen Appetite loss Hyperkalaemia Elevated alanine aminotransferase Elevated serum alkaline phosphatase Thrombocytosis Lymphopenia Gastrointestinal irritation Tremors Tiredness (lethargy) Not himself/herself
Outcomes: Ongoing

Dog, Shih Tzu, Female, 7 year, 7.9 kilogram • Drug: MSK, Capsule, Oral, Dose: 5 Milligram per animal, Frequency: 12 per hour • Reactions: Elevated serum alkaline phosphatase • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-055962
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 7.00 Year
  • Weight: 7.900 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Capsule
  • Dose: 5 Milligram per animal
  • Frequency: 12 per hour
Reactions Reported:
Elevated serum alkaline phosphatase
Outcomes: Outcome Unknown

Dog, Shiba Inu, Female, 6 year, 15 kilogram • Drug: MSK, Capsule, Oral, Dose: 40 Milligram per animal, Frequency: 24 per hour • Reactions: Elevated serum alkaline phosphatase, Hypocortisolaemia, Weight loss, Muscle atrophy, General illness • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-055961
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 6.00 Year
  • Weight: 15.000 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Capsule
  • Dose: 40 Milligram per animal
  • Frequency: 24 per hour
Reactions Reported:
Elevated serum alkaline phosphatase Hypocortisolaemia Weight loss Muscle atrophy General illness
Outcomes: Outcome Unknown

Dog, Terrier - Boston, Male, 10 year, 11.36 kilogram • Drug: MSK, Capsule, Oral, Dose: 20 Milligram per animal, Frequency: 24 per hour • Reactions: Vomiting, Tiredness (lethargy), Decreased appetite • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-055963
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 10.00 Year
  • Weight: 11.360 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Capsule
  • Dose: 20 Milligram per animal
  • Frequency: 24 per hour
Reactions Reported:
Vomiting Tiredness (lethargy) Decreased appetite
Outcomes: Recovered/Normal

Cat, Himalayan, Male, 12.5 year, 5.806 kilogram • Drug: MSK, Capsule, Oral, Dose: 5 Milligram per animal, Frequency: 12 per hour • Reactions: Weight loss, Unresponsive to stimuli, Hypernatremia, Decreased appetite, Anisocoria… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2021-US-023707
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 12.50 Year
  • Weight: 5.806 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Capsule
  • Dose: 5 Milligram per animal
  • Frequency: 12 per hour
Reactions Reported:
Weight loss Unresponsive to stimuli Hypernatremia Decreased appetite Anisocoria Hypoglycaemia Drug prescribing error
Outcomes: Outcome Unknown

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

Overdose can cause acute adrenal insufficiency with signs of collapse, severe weakness, and gastrointestinal upset. Immediate emergency treatment with IV fluids and corticosteroids is required.

Storage & Handling

Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and handle with care.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.